… families with hereditary breast-ovarian cancer. A prospective study of patient decision making and … -
C Lerman, S Narod, K Schulman, C Hughes, A Gomez- … - JAMA, 1996 - Am Med Assoc
... BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective
study of patient decision making and outcomes. C. Lerman ...

… in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the …
G Blackledge, F Lawton, C Redman, K Kelly - Br J Cancer, 1989 - ncbi.nlm.nih.gov
Response of patients in phase II studies of chemotherapy in ovarian cancer:
implications for patient treatment and the design of phase II trials. ...

… growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient … -
S Yamamoto, I Konishi, M Mandai, H Kuroda, T … - Br J Cancer, 1997 - ncbi.nlm.nih.gov
... Serum VEGF levels decreased after the successful removal of tumours in ovarian cancer
patients and, in one patient, the serum VEGF level was re-elevated during ...

… Compared With Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. -
WP McGuire, WJ Hoskins, MF Brady, PR Kucera, EE … - Obstetrical & Gynecological Survey, 1996 - obgynsurvey.com
... Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent
ovarian cancer. Anti-Cancer Drugs. 12(5):485-487, June 2001. ...

Use of proteomic patterns in serum to identify ovarian cancer -
EF Petricoin, AM Ardekani, BA Hitt, PJ Levine, VA … - The Lancet, 2002 - Elsevier
... increased risk of development of ovarian cancer; (2) this ... benign symptomless disorders
such as ovarian cysts?a ... in space for the unknown patient is compared ...

Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery … -
RE Bristow, MG del Carmen, HK Pannu, C Cohade, ML … - Gynecologic Oncology, 2003 - Elsevier
... All rights reserved. Regular article. Clinically occult recurrent ovarian cancer:
patient selection for secondary cytoreductive surgery using combined PET/CT *1 ...

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data … -
K Aabo, M Adams, P Adnitt, DS Alberts, A … - Br J Cancer, 1998 - ncbi.nlm.nih.gov
1998 Dec;78(11):1479-87. Chemotherapy in advanced ovarian cancer: four systematic
meta-analyses of individual patient data from 37 randomized trials. ...

… surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the … -
RE Bristow, LD Lagasse, BY Karlan - Cancer, 1996 - ncbi.nlm.nih.gov
Cancer. 1996 Nov 15;78(10):2049-62. Secondary surgical cytoreduction for advanced
epithelial ovarian cancer. Patient selection and review of the literature. ...

CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival -
G Kristiansen, C Denkert, K Schluns, E Dahl, C … - American Journal of Pathology, 2002 - ASIP
... Pathology Regular Articles. CD24 Is Expressed in Ovarian Cancer and Is a
New Independent Prognostic Marker of Patient Survival. Glen ...

… BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi … -
D Abeliovich, L Kaduri, I Lerer, N Weinberg, G … - Am J Hum Genet, 1997 - pubmedcentral.nih.gov
... One non-Ashkenazi Jewish ovarian cancer patient from Iraq carried the 185delAG
mutation. Individual mutation frequencies among breast ...